I talk about peptides a lot. I think peptide therapeutics are one of the most interesting areas of medicine right now, and I’m genuinely excited about where the science is going.
But there’s a corner of the peptide world that worries me more and more: products sold online labeled “research use only” or “not for human consumption” and then bought and injected by people at home.
Those three words aren’t a technicality. They matter.
So, what does “research use only” actually mean?
Back in 2021, right after I finished my fellowship and completed my peptide training, I got interested in a peptide being used off label in other countries for children with autism. There was a manufacturer abroad who could get it into the US, but only as a “research only” product. I’d never heard of that term before, so I started digging.
What I found surprised me. I could, in theory, run a research trial- but that requires an FDA investigational new drug (IND) application and oversight from an institutional review board (IRB). I wasn’t a research facility. I wasn’t tied to a lab. And there is no FDA registration you fill out to simply become a “researcher” so you can import and sell a foreign drug.
Here’s the part people miss: a “research only” label does not turn an unapproved drug into something you can legally market. The label doesn’t create a legal pathway- it just moves the liability.
Why the biology being exciting isn’t enough
Peptides are fascinating. They’re short chains of amino acids – usually fewer than about 40-50- that act as signaling molecules, and because of their size some can be compounded. The vial may look legitimate. The label may look professional. The website may even hand you a certificate of analysis.
None of that makes it an FDA-approved medication. And none of it tells me, as the clinician, what I’d actually want to know before I put a substance into a patient’s body.
Peptide research also varies enormously from one compound to the next – some have preclinical data only, some have early human data, very few have anything close to the standard we’d expect from an approved drug. The biology being interesting doesn’t automatically translate into clinical benefit for my patients, and we’re going to need time to see how these products hold up long term.
“But it has a COA…”
A certificate of analysis can be useful, but it is not the same thing as the manufacturing controls behind an FDA-approved injectable. A COA is a snapshot, not a guarantee of contaminants, batch-to-batch consistency, purity, potency, sterility, or endotoxin load.
And this isn’t a hypothetical concern. When third-party groups have actually tested gray-market peptides at scale- thousands of samples across hundreds of companies- more than 40% failed to meet basic purity and dosing standards, and a meaningful share of those tested for endotoxin had measurable amounts (Mendias & Awan, Sports Medicine, 2026). We also have hard history here: the FDA has overseen well over a hundred recalls of compounded drugs, including the 2012 contaminated-compound fungal meningitis outbreak that exposed more than 14,000 people (Woodcock & Dohm, NEJM, 2017). Sterility and quality are not paperwork problems. They’re patient-safety problems.
This is not an anti-peptide argument
I don’t want the increased FDA scrutiny to be read as “peptides are bad.” Honestly, I believe the opposite. Many peptides are showing relatively few reported adverse effects, patients are enjoying them, and they’re helping people appreciate how much cell signaling drives health.
One honest caveat: “few adverse effects” isn’t “proven safe.” BPC-157 drives blood-vessel growth via VEGF, yet human safety data barely exist- a couple of tiny pilots, one in just two people. Absence of data isn’t good data, and we should say so.
If these molecules are going to be part of longevity, metabolic medicine, and tissue repair, the answer is more research – not lower standards.
Why this is timely
This conversation got louder this year. This became especially timely after the FDA’s Pharmacy Compounding Advisory Committee met in July to evaluate several peptides familiar to the wellness and peptide community, including BPC-157, KPV, MOTS-c and TB-500. They recommended six of seven peptides for potential inclusion on the 503A Bulks List, despite FDA reviewers raising concerns about limited human safety and efficacy data. Whatever you think of any single molecule, that shift tells me something important: our patients are not waiting for randomized trials before they try these compounds.
So here’s where I land. Even if you never prescribe a single one of these peptides, you can still be part of the safety system. If a patient is using one, ask about it, monitor it, and report adverse events to the FDA through MedWatch. If as a patient, you experience side effects or symptoms, discuss with your provider. The FDA leans on clinician and consumer reports precisely because most of what happens in the compounding and gray-market space never gets reported (Woodcock & Dohm, NEJM, 2017).
We can be excited about peptides and demand better data at the same time. That’s not a contradiction. That’s just good medicine.